.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Citi
Julphar
Merck
Dow
Accenture
Boehringer Ingelheim
Healthtrust
Mallinckrodt
Cantor Fitzgerald

Generated: February 19, 2018

DrugPatentWatch Database Preview

Patents Expiring in December 2025

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms CorpNEVANACnepafenacSUSPENSION/DROPS;OPHTHALMIC021862-001Aug 19, 2005RXYesYes➤ Sign Up➤ Sign UpY
Takeda Pharms UsaNESINAalogliptin benzoateTABLET;ORAL022271-003Jan 25, 2013RXYesYes➤ Sign Up➤ Sign UpMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
Novartis Pharms CorpNEVANACnepafenacSUSPENSION/DROPS;OPHTHALMIC021862-001Aug 19, 2005RXYesYes➤ Sign Up➤ Sign UpY
Takeda Pharms UsaNESINAalogliptin benzoateTABLET;ORAL022271-002Jan 25, 2013RXYesNo➤ Sign Up➤ Sign UpMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
Takeda Pharms UsaNESINAalogliptin benzoateTABLET;ORAL022271-001Jan 25, 2013RXYesNo➤ Sign Up➤ Sign UpMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
Biogen IdecSPINRAZAnusinersen sodiumSOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes➤ Sign Up➤ Sign UpTREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE
Biogen IdecSPINRAZAnusinersen sodiumSOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes➤ Sign Up➤ Sign UpTREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA
Biogen IdecSPINRAZAnusinersen sodiumSOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes➤ Sign Up➤ Sign UpTREATMENT OF SPINAL MUSCULAR ATROPHY
Pfizer IncXELJANZ XRtofacitinib citrateTABLET, EXTENDED RELEASE;ORAL208246-001Feb 23, 2016RXYesYes➤ Sign Up➤ Sign UpY
Pf Prism CvXELJANZtofacitinib citrateTABLET;ORAL203214-001Nov 6, 2012RXYesYes➤ Sign Up➤ Sign UpY
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
McKinsey
Cantor Fitzgerald
US Army
Boehringer Ingelheim
Daiichi Sankyo
Deloitte
Chubb
Citi
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot